In prostate cancer, MAZ promotes bone metastasis through transcriptionally activating the KRas‐dependent RalGEFs pathway, and MAZ binds to the CDH1 promoter to promote epithelial‐mesenchymal transition (EMT) [12, 36]. Here, KRAS is linked to prostate cancer.